MicroRNAs in T Cell-Immunotherapy
Loading...
Official URL
Full text at PDC
Publication date
2022
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Citations
Exportar
Citation
Dosil, S.G.; Rodríguez-Galán, A.; Sánchez-Madrid, F.; Fernández-Messina, L. MicroRNAs in T Cell-Immunotherapy. Int. J. Mol. Sci. 2023, 24, 250. https://doi.org/10.3390/ijms24010250
Abstract
MicroRNAs (miRNAs) act as master regulators of gene expression in homeostasis and disease. Despite the rapidly growing body of evidence on the theranostic potential of restoring miRNA levels in pre-clinical models, the translation into clinics remains limited. Here, we review the current knowledge of miRNAs as T-cell targeting immunotherapeutic tools, and we offer an overview of the recent advances in miRNA delivery strategies, clinical trials and future perspectives in RNA interference technologies.
Description
Funding
This manuscript was funded by grants AEI/10.13039/501100011033, PID-2020-120412RB-I100 and PDC2021-121797-I00 (F.S.-M.) from the Spanish Ministry of Economy and Competitiveness; CAM (S2017/BMD-3671-INFLAMUNE-CM) from the Comunidad de Madrid (F.S.-M.), CIBERCV (CB16/11/00272) and BIOIMID PIE13/041 from the Instituto de Salud Carlos “la Caixa” Foundation under the project code HR17-00016. The current research is supported by AECC-Coordinated Grant 2022 (PRYCO223002PEIN). The CNIC is supported by the Ministerio de Ciencia, Innovacion y Universidades and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (MINECO, CEX2020-001039-S). S.G.D. is supported by a grant from the Spanish Ministry of Universities.